Researchers developed a simple injection that may support the heart during the vulnerable weeks after a heart attack. The treatment is given into skeletal muscle and prompts the body to release ANP, a natural hormone that reduces stress on the heart.
A study of the work in Science showed that a single dose produced ANP for several weeks. The injection uses self-amplifying RNA (saRNA), a technology related to some modern vaccines, so muscle cells make extra ANP for a limited time and the hormone travels to the heart to help repair.
The researchers say the shot could reduce scarring, preserve healthy heart muscle, improve pumping function and lower long-term complications. Before human trials, the team will test safety, timing and dosing.
Difficult words
- vulnerable — easily harmed or needing protection
- skeletal muscle — muscle attached to bones used for movement
- hormone — chemical from the body that controls activity
- self-amplifying RNA — RNA that makes more copies inside cells
- scar — mark left on tissue after injury healsscarring
- preserve — keep something in its original or good condition
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could a short-term injection that increases ANP change recovery after a heart attack for patients?
- What safety, timing, or dosing concerns should researchers check before they try this treatment in people?
- Would being treated by an injection into muscle feel more acceptable than a treatment given directly to the heart? Why or why not?
Related articles
Older adults more exposed to low-credibility online health information
Researchers at the University of Utah tracked web activity of more than 1,000 US adults for four weeks. They found low-credibility health sites were rare overall but visits were concentrated among older adults, especially those who lean right politically.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Psychedelics change blood-flow signals in brain imaging
Researchers at Washington University found that psychedelics acting on serotonin can disrupt the normal link between neuronal activity and blood flow in mice. Similar effects appeared with psilocybin and in reanalyzed human fMRI data.